IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$74.08-1.50 (-1.98%)
01:30 PM07:45 PM
News · 26 weeks124-36%
2025-10-262026-04-19
Mix6190d
- Insider35(57%)
- Other12(20%)
- SEC Filings9(15%)
- Analyst3(5%)
- Earnings1(2%)
- Leadership1(2%)
Latest news
25 items- SECSEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.DEFA14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECSEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.DEF 14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Ionis Pharma with a new price targetCanaccord Genuity initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $110.00
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen's positive impact on people living with this rare, often fatal neurological disease – – PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and pr
- INSIDERSEC Form 4 filed by Jenne Kyle4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Parshall B Lynne4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Birchler Brian4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Baroldi Joseph4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis to hold first quarter 2026 financial results webcastWebcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabol
- ANALYSTRaymond James resumed coverage on Ionis Pharma with a new price targetRaymond James resumed coverage of Ionis Pharma with a rating of Outperform and set a new price target of $104.00
- INSIDERSEC Form 4 filed by Klein Joseph Iii4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Devers Shannon L.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyThe approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of cli
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ionis Pharmaceuticals Inc.SCHEDULE 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- SECAmendment: SEC Form 144/A filed by Ionis Pharmaceuticals Inc.144/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- INSIDERSEC Form 4 filed by Schneider Eugene4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review– PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition, commonly resulting in progressive motor and cognitive dysfunction, loss of independence and is often fatal. There are no approved disease-modifying treatments, underscoring the significant
- INSIDERSEC Form 4 filed by Ionis Pharmaceuticals Inc.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERChief Executive Officer Monia Brett P sold $12,114,155 worth of shares (160,773 units at $75.35) and exercised 148,454 shares at a strike of $60.89, decreasing direct ownership by 5% to 242,662 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Ionis Pharmaceuticals Inc.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Ionis Pharmaceuticals Inc.4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis announces changes to Board of Directors– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter N. Reikes will be rejoining as a director. The changes will be effective June 4, 2026. Ms. Parshall has served as a director since September 2000. Previously, she served as Ionis' chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. Ms. Parshall joined Ionis in 1991 and served in various executive ro
- INSIDERDirector Klein Joseph Iii exercised 16,000 shares at a strike of $40.76 and sold $1,696,181 worth of shares (21,332 units at $79.51), decreasing direct ownership by 33% to 11,014 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)